BHARAT BIOTECH
COVID-19 Vaccination in India: Centre Creating ‘Artificial Scarcity’ of Coronavirus Vaccines To Benefit Bharat Biotech, Serum Institute', Says AAP Spokesperson Atishi
Health Ministry & NITI Aayog On Covishield-Covaxin Vaccine Mix-Up In Uttar Pradesh; ‘Significant Effect Unlikely If Doses Mixed,’ Says Centre
Pfizer Says Its Coronavirus Vaccine Effective Against B.1.6.1.7 Variant From India, Seeks Fast Track Approval
Covaxin Expected to Receive Regulatory Approval by WHO by July-September 2021, Says Bharat Biotech
COVID-19 Vaccine Update: Bharat Biotech Submits 90% of Documents to WHO for Emergency Use Listing for COVAXIN, Say Sources
Bharat Biotech Likely to Commence Trials of Covaxin, Its COVID-19 Vaccine, on Children from Next Month
COVID-19 Vaccination in India: Bharat Biotech to Ramp Up COVAXIN Production By 200 Million Doses
Covaxin Phase II and III Clinical Trials for 2–18 Age Group To Begin in 10–12 Days, Says Niti Aayog Member VK Paul
COVID-19 Vaccine Update: COVAXIN Phase II/III Clinical Trails in Age Group of 2 to 18 Years to Begin in 10-12 Days
COVAXIN Demonstrates Protection Against New Variants of COVID-19 Found in India & UK, Says Bharat Biotech
Gujarat Govt in Talks With Bharat Biotech To Ramp Up Production of Covaxin, Says Department of Biotechnology
Covaxin Manufacturing Plant of Bharat Biotech To Be Set Up in Kolar’s Malur Industrial Area, Says Karnataka Deputy CM Dr CN Ashwathnarayan
COVID-19 Vaccine Update: Hyderabad's Bharat Biotech to Start Producing Coronavirus Vaccines in Pune
50 Employees of Bharat Biotech Test COVID-19 Positive; Joint MD Suchitra Ella's Tweet Draws Bouquets and Brickbats
COVAXIN Phase 2 and 3 Trials for 2–18 Age Group Get DCGI Nod, Bharat Biotech To Conduct Trials on 525 Healthy Volunteers
COVAXIN Phase 2 and 3 Trials for 2 to 18 Age Group Approved by DCGI, Bharat Biotech To Conduct Trials on 525 Healthy Volunteers
Google Trends